Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of “Buy” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has received a consensus rating of “Buy” from the nine analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $59.8571.

A number of equities research analysts recently weighed in on OMCL shares. Benchmark restated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. KeyCorp lifted their price objective on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Craig Hallum reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Finally, UBS Group set a $60.00 price target on Omnicell and gave the company a “buy” rating in a research report on Friday, March 13th.

Omnicell Stock Up 1.0%

Omnicell stock opened at $41.93 on Thursday. The company has a market cap of $1.91 billion, a PE ratio of 95.30, a price-to-earnings-growth ratio of 1.07 and a beta of 0.96. Omnicell has a 1-year low of $26.84 and a 1-year high of $55.00. The stock’s 50 day moving average price is $41.48 and its 200 day moving average price is $41.52. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the prior year, the company posted $0.26 EPS. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, sell-side analysts predict that Omnicell will post 1.31 EPS for the current fiscal year.

Insider Activity

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by insiders.

Institutional Trading of Omnicell

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in shares of Omnicell during the 2nd quarter worth approximately $26,000. Clearstead Advisors LLC grew its holdings in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after buying an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Omnicell during the 4th quarter valued at $58,000. Parkside Financial Bank & Trust increased its position in Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after buying an additional 1,264 shares in the last quarter. Finally, First Horizon Corp increased its position in Omnicell by 54.6% during the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock worth $72,000 after buying an additional 564 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.